BDA‐410 inhibits SARS‐CoV‐2 main protease activity and viral replication in mammalian cells.

There is a precedent in using calpain inhibitors II and XII against SARS-CoV-2 3CLpro.8 BDA-410 (Mitsubishi Pharma) is a cysteine protease inhibitor that was originally developed as a relatively selective inhibitor of calpain-1 cysteine protease activity. Of note, our demonstration of BDA-410 as a potent inhibitor of SARS-CoV-2 cysteine protease activity and viral replication was originally peer reviewed prior to the disclosure of nirmatrelvir as a cysteine protease inhibitor. Keywords: BDA-410; Calpain-1; COVID-19; SARS-CoV-2 EN BDA-410 Calpain-1 COVID-19 SARS-CoV-2 5095 5098 4 10/13/22 20221001 NES 221001 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel highly virulent coronavirus that causes severe illness and mortality in certain patients. BDA-410 inhibits SARS-CoV-2 main protease activity and viral replication in mammalian cells. [Extracted from the article]